These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33908195)

  • 1. Is home-based therapy in Fabry disease the answer to compelling patients' needs during the COVID-19 pandemic? Survey results from the Polish FD Collaborative Group.
    Kusztal M; Kłopotowski M; Bazan-Socha S; Błażejewska-Hyżorek B; Pawlaczyk K; Oko A; Krajewska M; Nowicki M
    Adv Clin Exp Med; 2021 Apr; 30(4):449-454. PubMed ID: 33908195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued.
    Politei J
    Mol Genet Metab; 2020 Aug; 130(4):227-229. PubMed ID: 32561366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the COVID-19 pandemic on Fabry Disease Patients: an examination of Mood Status, Therapy Adherence, and COVID-19 infection.
    Karaca C; Dincer MT; Ozcan SG; Sarac B; Ahmadzada S; Alagoz S; Bakir A; Kiykim E; Trabulus S; Seyahi N
    Orphanet J Rare Dis; 2022 Sep; 17(1):338. PubMed ID: 36064417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents.
    Berry L; Walter J; Johnson J; Alton J; Powers J; Llòria X; Koulinska I; McGee M; Laney D
    Orphanet J Rare Dis; 2024 Apr; 19(1):153. PubMed ID: 38605390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond.
    Nowicki M; Bazan-Socha S; Kłopotowski M; Błażejewska-Hyżorek B; Kusztal M; Pawlaczyk K; Sławek J; Oko A; Oko-Sarnowska Z
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34443990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy.
    Barba-Romero MÁ; Serena J; Puig JM; Valverde C V; Climent V; Herrero JA; Huertas R; Torra R
    Med Clin (Barc); 2019 Jul; 153(2):47-55. PubMed ID: 30658922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group.
    Concolino D; Amico L; Cappellini MD; Cassinerio E; Conti M; Donati MA; Falvo F; Fiumara A; Maccarone M; Manna R; Matucci A; Musumeci MB; Nicoletti A; Nisticò R; Papadia F; Parini R; Peluso D; Pensabene L; Pisani A; Pistone G; Rigoldi M; Romani I; Tenuta M; Torti G; Veroux M; Zachara E
    Mol Genet Metab Rep; 2017 Sep; 12():85-91. PubMed ID: 28702361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of Place of Delivery during the COVID-19 Pandemic-Internet Survey in Polish Pregnant Women.
    Strózik M; Szarpak L; Adam I; Smereka J
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744094
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of COVID-19 pandemic on healthcare delivery for lysosomal storage disorders at a tertiary care public hospital in Mumbai.
    Muranjan M; Karande S; Rajoria S
    J Postgrad Med; 2024; 70(1):23-28. PubMed ID: 38197333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical care in Poland after COVID-19 outbreak: a national survey.
    Stefura T; Rymarowicz J; Wysocki M; Szeliga J; Wallner G; Pędziwiatr M; Nowakowski M; Major P
    Folia Med Cracov; 2020 Nov; 60(3):33-51. PubMed ID: 33582744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invisible burden of COVID-19: enzyme replacement therapy disruptions.
    Kahraman AB; Yıldız Y; Çıkı K; Akar HT; Erdal İ; Dursun A; Tokatlı A; Sivri HS
    J Pediatr Endocrinol Metab; 2021 May; 34(5):539-545. PubMed ID: 33818036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occupational risks for SARS-CoV-2 infection: the Polish experience.
    Sierpiński R; Pinkas J; Jankowski M; Juszczyk G; Topór-Mądry R; Szumowski Ł
    Int J Occup Med Environ Health; 2020 Oct; 33(6):781-789. PubMed ID: 32699423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occupational burnout among active physiotherapists working in clinical hospitals during the COVID-19 pandemic in south-eastern Poland.
    Pniak B; Leszczak J; Adamczyk M; Rusek W; Matłosz P; Guzik A
    Work; 2021; 68(2):285-295. PubMed ID: 33492259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
    Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
    Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Home-based infusion therapy--a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease].
    Beck M; Gaedeke J; Martus P; Karabul N; Rolfs A
    Dtsch Med Wochenschr; 2013 Nov; 138(46):2345-50. PubMed ID: 24193859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous enzyme replacement therapy: better in home or hospital?
    Milligan A; Hughes D; Goodwin S; Richfield L; Mehta A
    Br J Nurs; 2006 Mar 23-Apr 12; 15(6):330-3. PubMed ID: 16628169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.
    Vujasinovic M; Tepes B; Vujkovac B; Cokan Vujkovac A; Tretjak M; Korat V
    Wien Klin Wochenschr; 2015 Dec; 127(23-24):931-4. PubMed ID: 25835592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.